Having closed a complete of $40 million in its series B funding led by Daring, L’Oréal’s enterprise capital fund, biotech firm Debut desires to make the fragrance industry more sustainable.
“Having successfully scaled biotechnology with 100% success in skincare and leading that category, we are actually addressing the urgent challenges facing the fragrance industry,” said Debut founder and chief executive officer Joshua Britton.
By developing bio-identical and novel fragrance molecules, San Diego-based Debut believes it would enable fragrance brands to transition to bio-based formulas, while protecting the olfactive integrity of the formulas.
That’s because Debut’s biotechnology can replicate the olfactive signature and precise characteristics of natural ingredients, including those which can be structurally complex, difficult to source and only exist in trace amounts...
Continue reading